AbbVie Inc (ABBV.N)
|Market Cap (Mil.):||$76,801.94|
|Shares Outstanding (Mil.):||1,596.05|
LONDON - AbbVie, one of the two U.S. companies trying to stop Europe's drugs regulator from releasing previously secret clinical trials data, said on Thursday it had withdrawn lawsuits against the watchdog.
* Decision follows EMA acceptance of redactions to documents
LONDON, April 3 - AbbVie, one of the two U.S. firms bringing an injunction against Europe's drugs regulator over the issue of trial data secrecy, said on Thursday it had withdrawn its lawsuit.
Biosimilar drugs market
Feb 5 - U.S. drugmaker AbbVie Inc on Wednesday said it will spend $320 million to set up a manufacturing facility in Singapore to produce new drugs for cancer and immunology now in development.
- AbbVie Inc issued a cautious 2014 profit forecast, but said it expects U.S. approval this year for its potentially lucrative new all-oral treatment for hepatitis C, sending its shares up 3.4 percent.
Jan 31 - AbbVie Inc on Friday reported lower fourth-quarter earnings, hurt by generic competition for its medicines, but results matched Wall Street expectations.
- Gilead Sciences Inc released impressive late-stage data Wednesday for its once-daily combination pill to treat hepatitis C, advancing its lead in the race to develop new, all-oral treatments for the liver disease, and pushed up its timeline for seeking U.S. approval.
Dec 18 - Gilead Sciences Inc released impressive late-stage data Wednesday for its once-daily combination pill to treat hepatitis C, advancing its lead in the race to develop new, all-oral treatments for the liver disease, and pushed up its timeline for seeking U.S. approval.
- Women with an especially deadly type of breast cancer who received a treatment regimen containing an experimental AbbVie Inc drug prior to surgery are likely to have a significantly better response than those who get a standard chemotherapy regimen, according to data from a clinical trial.